Abstract
The article is an overview of the pharmacological effect of plasma derivative Haemocomplettan P which contains human fibrinogen concentrate. The drug is used primarily in the prevention and treatment of bleeding disorders in clinical practice, especially in the case of life threatening bleeding in obstetrics, anesthesiology and intensive care.
Haemocomplettan P is administered also in case of severe bleeding after anticoagulant therapy, including new oral direct anticoagulants, as specified by the current recommendations of the medical societies.